top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Apogee Secures $1.3B Blackstone Life Sciences Partnership to Advance Late-Stage Immunology Drug Development

  • 4 days ago
  • 1 min read

San Francisco, CA and Boston, MA, May 27, 2026 (Globe Newswire) -- Apogee Therapeutics has entered a strategic financing collaboration with Blackstone Life Sciences valued at $1.3 billion. The agreement will support Phase 3 development and potential commercialization of its immunology candidate zumilokibart. The funding is intended to accelerate late-stage clinical progress and prepare the program for possible market launch.


Read full article here.

 
 
 

Recent Posts

See All

Comments


Life Science Headlines
bottom of page